Información del artículo
La prática del trasplante de células progenitoras para las enfermedades autoinmunitarias severas refractarias a terapia convencional parte de dos descubrimientos: los excelentes resultados de los experimentos animales, y las observaciones descubiertas en humanos con enfermedades coincidentes. Los datos de los estudios experimentales y en fase temprana I-II en algunos pacientes altamente seleccionados sugieren que la quimioterapia a dosis elevadas seguidas por trasplante autólogo de progenitores hematopoyéticos (TPH) puede detener la progresión de enfermedades autoinmunitarias (EAI) severas con un aceptable riesgo/beneficio. En este artículo revisamos los ensayos en fase II-III prospectivos, multicéntricos, aleatorizados en diferentes EAI. Por otra parte, el trasplante alogénico de células progenitoras para EAI está siendo cautelosamente explorado en protocolos actuales.
Palabras clave:
Trasplante
Células progenitoras
Enfermedades autoinmunitarias
The use of stem cell transplantation for severe autoimmune diseases refractory to conventional therapy arose from two discoveries: the excellent results of animal experiments, and serendipitous observations in human coincidental diseases. Experimental data and early phase I-II trials in highly selected patients suggest that highdose chemotherapy followed by autologous hematopoietic stem cell transplantation can arrest progression of severe autoimmune diseases with an acceptable risk/benefit ratio. The present article reviews the phase II-III prospective, multicenter, randomized trials that have been performed in distinct autoimmunediseases. In addition, allogeneic stem cell transplantation for autoimmune diseases is being cautiously explored in current protocols.
Key words:
Transplantation
Stem cell
Autoimmune diseases
El Texto completo está disponible en PDF
Bibliografía
[1.]
E.A. Mayhall, N. Paffett-Lugassy, L.I. Zon.
The clinical potential of stem cells.
Curr Opin Cell Biol, 16 (2004), pp. 713-720
[2.]
K.M. Sullivan, D.E. Furst.
The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases.
J Rheumatol, 24 (1997), pp. 1-4
[3.]
S. Ikehara, M. Kawamura, F. Takao, et al.
Organ-specific and systemic autoimmune diseases in originate from defects in haematopoietic stem cell.
Proc Natl Acad Sci USA, 87 (1990), pp. 8341-8344
[4.]
J.A. Snowden, P.M. Brooks, J.C. Biggs.
Haematopoietic stem cell transplantation for autoimmune diseases.
Br J Haematol, 99 (1997), pp. 9-22
[5.]
J.M. Goldman, M.M. Horowitz.
The international bone marrow transplant registry.
Int J Hematol, 76 (2002), pp. 393-397
[6.]
A. Tyndall, A. Gratwohl.
Blood and marrow stem cell transplants in autoimmune diseases. A consensus report written on behalf of the European Group for Blood and Marrow Transplantation (EBMT) and the European League against Rheumatisms (EULAR).
Br J Rheumatol, 36 (1997), pp. 390-392
[7.]
R.K. Burt.
New indications in stem cell sources in trasplantation for autoimmune disease Blood and Bone Marrow.
Transplantation, 14 (2004), pp. 1-15
[8.]
I. Espigado, A. Marín, M. Rovira, et al.
Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results of the Spanish experience.
Transplant Proc, 35 (2003), pp. 742-743
[9.]
F.C. Breedveld, J.R. Kalden, J.S. Smolen.
Advances in targeted therapies: TNF alpha blockade in clinical practice.
Ann Rheum Dis, 58 (1999), pp. 1-130
[10.]
C. Bryan, C. Knight, C.M. Black, A. Silman.
Prediction of five year survival following presentation with scleroderma: development of a simple model using three disease factors at firs visit.
Arthritis Rheum, 42 (1999), pp. 2660-2665
[11.]
A. Tyndall, J. Passweg, A. Gratwohl.
Hematopoietic stem cell transplantation in the treatment of severe autoimmune diseases.
Ann Rheum Dis, 60 (2001), pp. 702-707
[12.]
J.A. Snowden, J. Passweg, J.J. Moore, et al.
Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
J Rheumatol, 31 (2004), pp. 482-488
[13.]
I.M. De Kleer, D.M. Brinkman, A. Forster, et al.
Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality and transplant related morbidity.
Ann Rheum Dis, 63 (2004), pp. 1318-1326
[14.]
A. Tyndall, A. Gratwohl.
Blood and marrow stem cell transplants in autoimmune diseases. A consensus report written on behalf of the European Group for Blood and Marrow Transplantation (EBMT) and the European League against Rheumatism (EULAR).
Br J Rheumatol, 36 (1997), pp. 390-392
[15.]
D. Farge, J.P. Marolleau, S. Zohar, et al.
Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.
Br J Haematol, 119 (2002), pp. 726-739
[16.]
D. Farge, J. Passweg, J.M. Van Laar, et al.
Autologous stem cell transplantation in the treatment of systemic sclerosis: report from EBMT/EULAR Registry.
Ann Rheum Dis, 63 (2004), pp. 974-981
[17.]
D.E. Furst, R. Nash, K.M. Sullivan, R. Saccardi, McSweeney.
High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward.
J Rheumatol, 31 (2004), pp. 2531-2535
[18.]
R.J. Verburg, J.K. Sont, J.M. Van Laar.
Reduction of joint damage in severe Rheumatoid Arthritis by high-dose chemotherapy and autologous stem transplantation.
Arthritis Rheumatims, 52 (2005), pp. 421-424
[19.]
R.K. Burt, B.A. Cohen, E. Russell, et al.
Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of intense immune suppression to prevent disease progression in patients with high disability scores.
Blood, 102 (2003), pp. 2373-2378
[20.]
R. Saccardi, A. Tyndall, G. Coghlan, et al.
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.
Bone Marrow Transplant, 34 (2004), pp. 877-881
[21.]
A. Tyndall, R. Saccardi.
Haematopoietic stem cell transplantation in the treatment of autoimmune diseases; results from phase I/II studies, prospective, randomized trials and future directions.
Clinical and Experimental Immunol, 141 (2005), pp. 1-9
[22.]
A. Gratwohl, J. Passweg, C. Bocelli-Tyndall, et al.
Autologous haematopoietic stem cell transplantation for autoimmune diseases.
Bone Marrow Transplant, 35 (2005), pp. 869-879
[23.]
I. Espigado, J.M. Rodríguez, E. Carreras.
Trasplante autólogo de progenitores hematopoyéticos en enfermedades autoinmunes.
Methods and Findings in Experimental and Clinical Pharmacology, 24 (2002), pp. 103-108
[24.]
I. Espigado, A. García López, A. Valenzuela, J.M. Fernández.
Autotrasplante de progenitores hematopoyéticos en una paciente con artritis reumatoide.
Med Clin, 10 (2001), pp. 399
[25.]
Y. Oyama, R.M. Craig, A.E. Traynor, et al.
Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease.
Gastroenterology, 128 (2005), pp. 786-789
[26.]
Y. Oyama, E.R. Parker, J. Brieva, et al.
High dose immunosupresion and autologous stem cell transplantation in refractory pemphigus foliaceus.
Bone Marrow Transplant, 34 (2004), pp. 1097-1098
[27.]
R. Verburg, R. Flierman, J.K. Sont, et al.
The outcome of intensive immunosupresion and autologous stem cell transplantation in patients with severe rheumatoid arthritis in associated with the composition of synovial T cell infiltration.
Ann Rheum Dis, 64 (2005), pp. 1397-1405
[28.]
J.M. Van Laar.
Immune ablation and stem-cell therapy in autoimmune diseases. Immunological reconstitution after high-dose immunosupression and haematopoietic stem-cell transplantation.
Arthritis Res, 2 (2000), pp. 270-275
[29.]
R.P. Gale, Y. Reisner.
Graft rejection and graft-versus-host disease: mirror images.
Lancet, 1 (1986), pp. 1468-1470
[30.]
Y. Oyama, A.E. Traynor, W. Barr, R.K. Burt.
Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.
Bone Marrow Transplant, 32 (2003), pp. 581-583
[31.]
J.R. Passweg, M. Rabusin, M. Musso, et al.
Haematopoietic stem cell transplantation for refractory autoimmune cytopenia.
Br J Haematol, 125 (2004), pp. 749-755
[32.]
R.A. Nash.
Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens.
Bone Marrow Transplant, 32 (2003), pp. S77-S80
[33.]
S.Z. Pavletic.
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune diseases.
Arthritis Rheum, 50 (2004), pp. 2378-2390
[34.]
R.K. Burt, Y. Oyama, L. Verda, et al.
Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism.
Arthritis Rheum, 50 (2004), pp. 2466-2470
[35.]
M.K. Brenner.
Haematopoietic stem cell transplantation for autoimmune diseases limits and future potential.
Best Pract Res Clin Haematol, 17 (2004), pp. 359-374
Copyright © 2006. Elsevier España S.L. Barcelona
